Management of treatment-emergent peripheral neuropathy in multiple myeloma.
about
Pomalidomide is nonteratogenic in chicken and zebrafish embryos and nonneurotoxic in vitroTreatment of relapsed and refractory multiple myelomaNeuropathic cancer pain: What we are dealing with? How to manage it?International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantationA clinical update on the role of carfilzomib in the treatment of relapsed or refractory multiple myelomaRecent advances in multiple myeloma: a Korean perspectiveClinical use of proteasome inhibitors in the treatment of multiple myelomaCarfilzomib and pomalidomide in patients with relapsed and/or refractory multiple myeloma with baseline risk factorsReview of health-related quality of life data in multiple myeloma patients treated with novel agents.Phase II study of bortezomib-dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myelomaEfficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study.A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myelomaExpert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myelomaPhase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma.Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patientsPhase II study of bortezomib in combination with rituximab, cyclophosphamide and prednisone with or without doxorubicin followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma.Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies.Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma.Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis.Electroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy in multiple myeloma: a feasibility study.Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapyIntegrated systems pharmacology analysis of clinical drug-induced peripheral neuropathy.The positive effects of one-hour intravenous administration of bortezomib on peripheral neuropathy in multiple myeloma patientsSubclinical peripheral neuropathy in patients with multiple myeloma before chemotherapy is correlated with decreased fingertip innervation densityHealth care costs and resource utilization, including patient burden, associated with novel-agent-based treatment versus other therapies for multiple myeloma: findings using real-world claims data.Central neurotoxicity of immunomodulatory drugs in multiple myeloma.Longitudinal analysis of patient-reported symptoms post-autologous stem cell transplant and their relationship to inflammation in patients with multiple myelomaEuropean perspective on multiple myeloma treatment strategies: update following recent congressesEuropean Myeloma Network guidelines for the management of multiple myeloma-related complications.Immune modulation therapy in the management of bortezomib-induced peripheral neuropathy.The protective effects of lafutidine for bortezomib induced peripheral neuropathy.Bortezomib-related neuropathy may mask CNS relapse in multiple myeloma: A call for diligence.Pharmacokinetics of ixazomib, an oral proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairmentEffect of general symptom level, specific adverse events, treatment patterns, and patient characteristics on health-related quality of life in patients with multiple myeloma: results of a European, multicenter cohort studyProteasome inhibitors in multiple myeloma: 10 years later.Effective induction therapy with subcutaneous administration of bortezomib for newly diagnosed POEMS syndrome: a case report and a review of the literature.Successful treatment with bortezomib in type-1 cryoglobulinemic vasculitis patient after rituximab failure: a case report and literature review.Non-coding RNA: a novel opportunity for the personalized treatment of multiple myeloma.International Myeloma Working Group recommendations for global myeloma care.Current strategies for treatment of relapsed/refractory multiple myeloma.
P2860
Q24634078-84CCBAFC-F5C6-4870-BFA5-0713A4B2DE85Q26749180-FB71C152-2943-4DC9-B61C-2F26B8EC387DQ26998945-3693895A-0D93-4F33-84E6-3330445ADCE7Q27002668-95F04AA1-8604-43F3-8383-8221381B5DFFQ28067148-5B34BEA7-CDF0-43C0-A3F4-9F4CC7388325Q28074521-B7CBD7DB-BE80-42AE-AE73-E3E5AEB19AD6Q28080999-EB873C4D-DF4E-4E42-87AE-C7240887B1BFQ28084683-A9E330D6-184A-4AF5-B8D7-0602BC17711BQ30650394-C7B3A051-E9E7-48E5-9AAA-558D5C7B9B54Q33408056-149E464D-6D9B-4807-81A5-71F73C9EAE26Q33411708-1AF96C00-8154-467D-A468-6C52E6B3F937Q33412684-E4329B8D-970E-4213-BD62-A9CCD5C36CCDQ33413142-11AE3C89-1176-4DAE-82CE-20876822707AQ33415759-5CD9136B-AB14-454B-B4F9-46D2E753CCAAQ33415893-EAD25836-571A-419F-A45A-9F22D8DAA7CEQ33416533-181613B7-631D-402C-9521-D6F9EF4E5E50Q33421241-6C2FEBB8-DC46-484B-9145-C3E7C7D1B5D0Q33441702-C4D0391C-7969-4410-AEAE-20614A684024Q33441845-676D5317-A2C4-4138-A4E7-13C4EE218882Q33684190-5181BA98-5B33-4662-A50C-CC9A59B9F2D0Q33696008-8FA279E8-4A84-433B-9807-0277EBEBE301Q33733061-9942AC53-7835-4CC4-98AD-CCA294C920EEQ33787025-2CFFC46B-A846-4E00-ADB2-82C0D90E9E66Q34226021-CCFAFA59-D754-42B6-A26C-099B5C9CAB67Q34539519-B5A84165-F56F-426E-BCD2-A5B488D6405EQ35228770-795641DD-383C-4278-99B0-7DE7C0B29C16Q35630256-58D403AE-1A63-40E0-A74C-4E66DE7E1BBDQ35989943-BC0D3036-14AF-4C51-A5A7-4B7574739523Q36115636-03E297D6-BC61-43CC-85A0-64D8493E3392Q36444453-8F4E45F4-6B8F-49C1-9974-EFCD90C0B9DFQ37017164-A906E225-7CF3-41B4-A003-6EF7E2534529Q37146294-5244F3AA-5AB9-44C3-B726-CC7E67896C16Q37384878-88E707E1-7DAF-466E-B7E2-816676E71C4CQ37440614-D08C9BBD-779C-46CC-B33A-A39AB1D40D62Q38014395-D321C8F3-ACAA-4E3B-864B-C7D8C66DEC24Q38061553-F0F65DA1-8699-4713-9BA4-37E975841452Q38101526-1C40C8EF-FA41-423C-82A1-818AAC66032CQ38108387-AE99B42D-74C9-462D-8D8D-EDADFE8A6446Q38157532-E1FF42AE-C27E-471B-A01E-B6EBD36E3D62Q38182683-F541D80D-F996-4AAE-A77D-AE87BA068E77
P2860
Management of treatment-emergent peripheral neuropathy in multiple myeloma.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Management of treatment-emergent peripheral neuropathy in multiple myeloma.
@en
Management of treatment-emergent peripheral neuropathy in multiple myeloma.
@nl
type
label
Management of treatment-emergent peripheral neuropathy in multiple myeloma.
@en
Management of treatment-emergent peripheral neuropathy in multiple myeloma.
@nl
prefLabel
Management of treatment-emergent peripheral neuropathy in multiple myeloma.
@en
Management of treatment-emergent peripheral neuropathy in multiple myeloma.
@nl
P2093
P50
P356
P1433
P1476
Management of treatment-emergent peripheral neuropathy in multiple myeloma
@en
P2093
A Mazumder
B G M Durie
J J Lahuerta
P2888
P304
P356
10.1038/LEU.2011.346
P50
P577
2011-12-23T00:00:00Z